High-throughput screening and small animal models, where are we?

被引:206
作者
Giacomotto, Jean [1 ]
Segalat, Laurent [1 ]
机构
[1] Univ Lyon 1, CGMC, CNRS UMR5534, F-69622 Villeurbanne, France
关键词
Caenorhabditis elegans; Drosophila melanogaster; Danio rerio; high throughput screening; drug discovery; chemical genetics; disease; drug target; SMALL-MOLECULE SCREEN; CAENORHABDITIS-ELEGANS; C-ELEGANS; DROSOPHILA-MELANOGASTER; HUMAN-DISEASE; ZEBRAFISH MODEL; TARGET IDENTIFICATION; SYSTEMATIC ANALYSIS; AUTOMATED-ANALYSIS; DRUG DISCOVERY;
D O I
10.1111/j.1476-5381.2010.00725.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Current high-throughput screening methods for drug discovery rely on the existence of targets. Moreover, most of the hits generated during screenings turn out to be invalid after further testing in animal models. To by-pass these limitations, efforts are now being made to screen chemical libraries on whole animals. One of the most commonly used animal model in biology is the murine model Mus musculus. However, its cost limit its use in large-scale therapeutic screening. In contrast, the nematode Caenorhabditis elegans, the fruit fly Drosophila melanogaster, and the fish Danio rerio are gaining momentum as screening tools. These organisms combine genetic amenability, low cost and culture conditions that are compatible with large-scale screens. Their main advantage is to allow high-throughput screening in a whole-animal context. Moreover, their use is not dependent on the prior identification of a target and permits the selection of compounds with an improved safety profile. This review surveys the versatility of these animal models for drug discovery and discuss the options available at this day.
引用
收藏
页码:204 / 216
页数:13
相关论文
共 50 条
  • [1] In vivo quantitative high-throughput screening for drug discovery and comparative toxicology
    Dranchak, Patricia K.
    Oliphant, Erin
    Queme, Bryan
    Lamy, Laurence
    Wang, Yuhong
    Huang, Ruili
    Xia, Menghang
    Tao, Dingyin
    Inglese, James
    DISEASE MODELS & MECHANISMS, 2023, 16 (03)
  • [2] High-throughput screening in academia: The Harvard experience
    Stein, RL
    JOURNAL OF BIOMOLECULAR SCREENING, 2003, 8 (06) : 615 - 619
  • [3] The future of high-throughput screening
    Mayr, Lorenz M.
    Fuerst, Peter
    JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (06) : 443 - 448
  • [4] A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
    Fouda, Ahmed
    Tahsini, Mahasti
    Khodayarian, Fatemeh
    Al-nafisah, Fatimah
    Rafei, Moutih
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2017, (121):
  • [5] High-Content and High-Throughput In Vivo Drug Screening Platforms Using Microfluidics
    Ben-Yakar, Adela
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2019, 17 (01) : 8 - 13
  • [6] High-throughput screening for kinase inhibitors
    von Ahsen, O
    Bömer, U
    CHEMBIOCHEM, 2005, 6 (03) : 481 - 490
  • [7] High-Throughput Screening
    Wildey, Mary Jo
    Haunso, Anders
    Tudor, Matthew
    Webb, Maria
    Connick, Jonathan H.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 50: PLATFORM TECHNOLOGIES IN DRUG DISCOVERY AND VALIDATION, 2017, 50 : 149 - 195
  • [8] Cell-Based Assays for High-Throughput Screening
    An, W. Frank
    Tolliday, Nicola
    MOLECULAR BIOTECHNOLOGY, 2010, 45 (02) : 180 - 186
  • [9] Advances in ion channel high throughput screening: where are we in 2023?
    Dallas, Mark L.
    Bell, Damian
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (03) : 331 - 337
  • [10] High-throughput screening: Update on practices and success
    Fox, Sandra
    Farr-Jones, Shauna
    Sopchak, Lynne
    Boggs, Amy
    Nicely, Helen Wang
    Khoury, Richard
    Biros, Michael
    JOURNAL OF BIOMOLECULAR SCREENING, 2006, 11 (07) : 864 - 869